Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics announced the acquisition of Prana Therapies in a stock-for-stock merger, concurrently raising $120 million in upfront private placement financing with potential for an additional $60 million. The combined entity will prioritize the advancement of Prana's lead program, PRA-216, a bispecific antibody targeting IL-4Rα/TSLP, through Phase 2 development for inflammatory diseases. The transaction is expected to provide sufficient funding into 2028. Sheila Gujrathi, former CEO of Prana, has joined Bolt's executive team as Chief Strategy Officer and the Board of Directors.

Bolt Biotherapeutics, Inc. reported a net loss of $(7.7) million for the second quarter of 2026 and $(15.0) million for the first six months of 2026. The company's management has raised substantial doubt about its ability to continue as a going concern, stating that its cash and marketable securities of $18.1 million as of June 30, 2026, are not sufficient to fund operations for at least one year. The company will need to secure additional capital through partnering, equity sales, or other financing methods.

Bolt Biotherapeutics reported a significant decline in Q1 2026 collaboration revenue to $26,000, a 98% drop year-over-year. Despite this, the company's net loss improved to $7.2 million from $11.0 million in Q1 2025, driven by reduced operating expenses. However, management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash and marketable securities to fund operations for at least one year.

Bolt Biotherapeutics reported a net loss of $7.2 million for the first quarter ended March 31, 2026, an improvement from $11.0 million in the prior year, primarily due to reduced R&D and G&A expenses. The company's cash balance of $23.9 million is anticipated to fund operations into 2027. Bolt's lead immune-stimulating antibody conjugate, BDC-4182, is progressing in its Phase 1/2 study, with initial clinical data expected in the third quarter of 2026.

Bolt Biotherapeutics reported a net loss of $7.2 million for the first quarter ended March 31, 2026, with R&D expenses decreasing to $4.8 million and G&A expenses to $2.8 million due to restructuring. The company announced that initial clinical data from its BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer is expected in the third quarter of 2026. Bolt's cash balance of $23.9 million as of March 31, 2026, is projected to fund operations into 2027, including the completion of the BDC-4182 dose escalation.

Bolt Biotherapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 11:00 a.m. Pacific Time. Stockholders of record as of April 22, 2026, will vote on the election of two Class II directors, William P. Quinn and Jakob Dupont, M.D., and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. The company also noted a 1-for-20 reverse stock split was effected on June 6, 2025.